Erin Quirk is Chief Medical Officer of Terns Pharmaceuticals.  Previously, Dr. Quirk was Vice President of Clinical Research at Gilead Sciences, where she oversaw clinical development activities for investigational HIV treatments, as well as the development strategy and life-cycle maintenance for the company’s HIV portfolio.   Prior to joining Gilead, Dr. Quirk was Director of Clinical Research at Merck Research Laboratories, where she advanced clinical trials for HIV vaccines and small molecules for hepatitis C virus infection.  During her time in the pharmaceutical industry, Dr. Quirk has progressed numerous small molecule, biologic and vaccine candidates into clinical trials and through the drug development process, leading teams to achieve global approvals of multiple new therapies for life-threatening diseases. 


Dr. Quirk holds a bachelor’s degree from Drew University and an MD from the University of Colorado.  She completed training in internal medicine and infectious diseases at Washington University in St. Louis where she was a faculty member prior to joining the pharmaceutical industry.